<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00598403</url>
  </required_header>
  <id_info>
    <org_study_id>TM-ME1207/311</org_study_id>
    <secondary_id>2007-001486-15</secondary_id>
    <nct_id>NCT00598403</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Cefditoren Pivoxil Versus Ciprofloxacin in Acute Uncomplicated Cystitis</brief_title>
  <official_title>Multicentre, Prospective, Comparative, Randomized, Double-blind, Double-dummy Study to Assess the Efficacy and Safety of Cefditoren Pivoxil vs. Ciprofloxacin in Uncomplicated Acute Cystitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tedec-Meiji Farma, S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tedec-Meiji Farma, S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the study is to comparatively assess the efficacy and tolerability of
      the drugs under study in the treatment of acute uncomplicated cystitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Urinary tract infections (UTI) are one of the most frequent reasons of surgery visits in
      Primary Care. More than 95 percent of UTIs are monomicrobial, although the microorganisms
      implied are varied, and the range of effective drugs could be extensive. The species most
      frequently isolated is Escherichia coli, with prevalence ranking between 85 and 90 percent of
      documented cases. E. coli has developed resistance to different antibiotics. Cefditoren is
      situated as a good candidate for the treatment of uncomplicated UTIs due to its spectrum of
      activity against E. coli. The study has been designed in accordance with the guidelines and
      recommendations in force to assess the efficacy of cefditoren pivoxil against ciprofloxacin,
      a drug which despite the increasing rate of resistance in some countries, continues to be a
      drug of choice for the treatment of uncomplicated UTIs.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Microbiological efficacy</measure>
    <time_frame>5-9 days post-therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical efficacy</measure>
    <time_frame>5-9 days post-therapy</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">611</enrollment>
  <condition>Urinary Tract Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cefditoren pivoxil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ciprofloxacin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cefditoren pivoxil</intervention_name>
    <description>400 mg, oral, single dose during 3 days</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Meiact, Spectracef, Telo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofloxacin</intervention_name>
    <description>250 mg, oral, twice a day for 3 days</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Ciprofloxacino Mabo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-pregnant adult females (&gt;= 18)

          -  Clinical signs and symptoms of uncomplicated acute cystitis (dysuria, urgency,
             frequency, suprapubic pain) with symptoms starting &lt;=72 hours prior the study entry

          -  Positive pre-treatment clean-catch midstream urine culture (&gt;= 103 CFU/ml) and pyuria
             (10 leukocytes/mm3 or more than 5 leukocytes/field 40x magnification) within the 48
             hours prior to inclusion in the study

          -  In vitro susceptibility testing of the isolated uropathogen to the drugs under study

          -  Written informed consent

        Exclusion Criteria:

          -  Males

          -  Woman who are pregnant, nursing or not using a medically accepted, effective method of
             birth control

          -  Three or more episodes of uncomplicated acute infections of the urinary tract during
             the past 12 months

          -  Symptoms starting &gt;4 days prior to admission

          -  Body temperature &gt;= 38.3ºC, back pain, chills or other manifestations suggestive of
             upper urinary infection

          -  Evidence of structural or functional alterations of the urinary tract, such as
             calculi, stenosis, primary renal disease (eg. polycystic renal disease) or neurogenic
             bladder

          -  Underlying disease predisposing to complicated urinary tract infections such as
             diabetes mellitus, immunosuppression, leucopenia, heart insufficiency, liver
             impairment and neoplastic processes
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose L Ballve</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Josep R Toll</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Rosa Viñas</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Rosaura Figueras</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Joan Palou</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Gabriel Martín</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Ramon Pons</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Manel Terns</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Josep L Fernandez</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Pere Toran</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Pilar Montero</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Bingen Uriondo</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Pablo Daza</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Jesus Zorita</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Ander Larrazabal</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Natividad Gonzalez</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Jose F Magdalena</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Fernando Martin</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Jose Porta</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Mª Rosa Magallon</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Mª Sol Reixa</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Jesus Torrecilla</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Isabel Blasco</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Antonio Hidalgo</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Alicia Alvarez</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Gabriel Romera</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Estrella Castro</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Manuel M Ortega</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Salvador Pertusa</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Manuel Ramirez</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Aggelos Pefanis</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Chatzimouratidis</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Jose V Vaquer</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Nicolas Salvador</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Jose L Pardo</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Joaquin Aracil</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Mª Jesus Barreda</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Artemio Alvarez</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Vicente Lopez</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Panagiotis Gargalianos</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Dolores M Maestre</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>General Hospital of Chest Disease of Athens</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Thessaloniki</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CS Rincón de Loix</name>
      <address>
        <city>Benidorm</city>
        <state>Alicante</state>
        <zip>03500</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAP Cornella</name>
      <address>
        <city>Cornella de Llobregat</city>
        <state>Barcelona</state>
        <zip>08940</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAP 17 setembre</name>
      <address>
        <city>El Prat de Llobregat</city>
        <state>Barcelona</state>
        <zip>08820</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAP Bartomeu Fabres Anglada</name>
      <address>
        <city>Gava</city>
        <state>Barcelona</state>
        <zip>08850</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAP Amadeu Torner</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08902</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAP Florida Nord</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08905</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAP Dr. Vicens Papaceit</name>
      <address>
        <city>La Roca del Valles</city>
        <state>Barcelona</state>
        <zip>08430</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAP Les Bases-Manresa 3</name>
      <address>
        <city>Manresa</city>
        <state>Barcelona</state>
        <zip>08243</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAP La Riera</name>
      <address>
        <city>Mataro</city>
        <state>Barcelona</state>
        <zip>08302</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAP El Maresme</name>
      <address>
        <city>Mataro</city>
        <state>Barcelona</state>
        <zip>08303</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAP Navas-Balsareny</name>
      <address>
        <city>Navas</city>
        <state>Barcelona</state>
        <zip>08670</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAP Remei</name>
      <address>
        <city>Vic</city>
        <state>Barcelona</state>
        <zip>08500</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CS San Telmo</name>
      <address>
        <city>Jerez de la frontera</city>
        <state>Cadiz</state>
        <zip>11408</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CS Cabra</name>
      <address>
        <city>Cabra</city>
        <state>Cordoba</state>
        <zip>14940</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CS Lucena</name>
      <address>
        <city>Lucena</city>
        <state>Cordoba</state>
        <zip>14900</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CS Rute</name>
      <address>
        <city>Rute</city>
        <state>Cordoba</state>
        <zip>14960</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CS Billabona</name>
      <address>
        <city>Billabona</city>
        <state>Guipuzcoa</state>
        <zip>20150</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CS Legazpi</name>
      <address>
        <city>Legazpi</city>
        <state>Guipuzcoa</state>
        <zip>20230</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CS Monzón Urbano</name>
      <address>
        <city>Monzon</city>
        <state>Huesca</state>
        <zip>22400</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CS Basurto</name>
      <address>
        <city>Bilbao</city>
        <state>Vizcaya</state>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CS Cabo Huertas</name>
      <address>
        <city>Alicante</city>
        <zip>03540</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAP El Clot</name>
      <address>
        <city>Barcelona</city>
        <zip>08018</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Puigvert</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CS Sagasta Ruiseñores</name>
      <address>
        <city>Zaragoza</city>
        <zip>50006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CS Torrero La Paz</name>
      <address>
        <city>Zaragoza</city>
        <zip>50007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CS Torre Ramona</name>
      <address>
        <city>Zaragoza</city>
        <zip>50013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CS Arrabal</name>
      <address>
        <city>Zaragoza</city>
        <zip>50015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CS Bombarda</name>
      <address>
        <city>Zaragoza</city>
        <zip>50017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2008</study_first_submitted>
  <study_first_submitted_qc>January 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2008</study_first_posted>
  <last_update_submitted>June 28, 2010</last_update_submitted>
  <last_update_submitted_qc>June 28, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 29, 2010</last_update_posted>
  <responsible_party>
    <name_title>Mercedes Gimeno/ R&amp;D Director</name_title>
    <organization>Tedec-Meiji Farma, S.A.</organization>
  </responsible_party>
  <keyword>Cystitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Tract Infections</mesh_term>
    <mesh_term>Cystitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>Cefditoren</mesh_term>
    <mesh_term>Cefditoren pivoxil</mesh_term>
    <mesh_term>Cephalosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

